Trimethoprim-sulfamethoxazole therapy for shigellosis.

J. D. Nelson, H. Kusmiesz, L. H. Jackson, E. Woodman

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Twenty-eight infants and children hospitalized for severe shigellosis were treated orally either with ampicillin trihydrate (100 mg/kg/day administered in divided doses every six hours) or with trimethoprim-sulfamethoxazole (trimethoprim, 10 mg; sulfamethoxazole, 50 mg/kg/day in divided doses every 12 hours) for five days. Four patients with ampicillin-resistant shigellae continued to have diarrhea and positive stool cultures during therapy. Patients with susceptible shigellae treated with ampicillin and all patients treated with trimethoprim-sulfamethoxazole responsed promptly and comparably within an average of 1.6 and 1.7 days, respectively, until stool cultures were negative, and 3.1 and 2.9 days, respectively, until diarrhea stopped. Patients with ampicillin-resistant shigellae responded to treatment with trimethoprim-sulfamethoxazole. It is concluded that trimethoprim-sulfamethoxazole is the best currently available drug for treatment of shigellosis in areas where multiple antibiotic resistance of shigellae is common.

Original languageEnglish (US)
Pages (from-to)1239-1243
Number of pages5
JournalJournal of the American Medical Association
Volume235
Issue number12
DOIs
StatePublished - Mar 22 1976

Fingerprint

Bacillary Dysentery
Shigella
Sulfamethoxazole Drug Combination Trimethoprim
Ampicillin
Diarrhea
Sulfamethoxazole
Trimethoprim
Hospitalized Child
Therapeutics
Microbial Drug Resistance
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Trimethoprim-sulfamethoxazole therapy for shigellosis. / Nelson, J. D.; Kusmiesz, H.; Jackson, L. H.; Woodman, E.

In: Journal of the American Medical Association, Vol. 235, No. 12, 22.03.1976, p. 1239-1243.

Research output: Contribution to journalArticle

Nelson, J. D. ; Kusmiesz, H. ; Jackson, L. H. ; Woodman, E. / Trimethoprim-sulfamethoxazole therapy for shigellosis. In: Journal of the American Medical Association. 1976 ; Vol. 235, No. 12. pp. 1239-1243.
@article{c3a508460fc34360a04595789eacb176,
title = "Trimethoprim-sulfamethoxazole therapy for shigellosis.",
abstract = "Twenty-eight infants and children hospitalized for severe shigellosis were treated orally either with ampicillin trihydrate (100 mg/kg/day administered in divided doses every six hours) or with trimethoprim-sulfamethoxazole (trimethoprim, 10 mg; sulfamethoxazole, 50 mg/kg/day in divided doses every 12 hours) for five days. Four patients with ampicillin-resistant shigellae continued to have diarrhea and positive stool cultures during therapy. Patients with susceptible shigellae treated with ampicillin and all patients treated with trimethoprim-sulfamethoxazole responsed promptly and comparably within an average of 1.6 and 1.7 days, respectively, until stool cultures were negative, and 3.1 and 2.9 days, respectively, until diarrhea stopped. Patients with ampicillin-resistant shigellae responded to treatment with trimethoprim-sulfamethoxazole. It is concluded that trimethoprim-sulfamethoxazole is the best currently available drug for treatment of shigellosis in areas where multiple antibiotic resistance of shigellae is common.",
author = "Nelson, {J. D.} and H. Kusmiesz and Jackson, {L. H.} and E. Woodman",
year = "1976",
month = "3",
day = "22",
doi = "10.1001/jama.235.12.1239",
language = "English (US)",
volume = "235",
pages = "1239--1243",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Trimethoprim-sulfamethoxazole therapy for shigellosis.

AU - Nelson, J. D.

AU - Kusmiesz, H.

AU - Jackson, L. H.

AU - Woodman, E.

PY - 1976/3/22

Y1 - 1976/3/22

N2 - Twenty-eight infants and children hospitalized for severe shigellosis were treated orally either with ampicillin trihydrate (100 mg/kg/day administered in divided doses every six hours) or with trimethoprim-sulfamethoxazole (trimethoprim, 10 mg; sulfamethoxazole, 50 mg/kg/day in divided doses every 12 hours) for five days. Four patients with ampicillin-resistant shigellae continued to have diarrhea and positive stool cultures during therapy. Patients with susceptible shigellae treated with ampicillin and all patients treated with trimethoprim-sulfamethoxazole responsed promptly and comparably within an average of 1.6 and 1.7 days, respectively, until stool cultures were negative, and 3.1 and 2.9 days, respectively, until diarrhea stopped. Patients with ampicillin-resistant shigellae responded to treatment with trimethoprim-sulfamethoxazole. It is concluded that trimethoprim-sulfamethoxazole is the best currently available drug for treatment of shigellosis in areas where multiple antibiotic resistance of shigellae is common.

AB - Twenty-eight infants and children hospitalized for severe shigellosis were treated orally either with ampicillin trihydrate (100 mg/kg/day administered in divided doses every six hours) or with trimethoprim-sulfamethoxazole (trimethoprim, 10 mg; sulfamethoxazole, 50 mg/kg/day in divided doses every 12 hours) for five days. Four patients with ampicillin-resistant shigellae continued to have diarrhea and positive stool cultures during therapy. Patients with susceptible shigellae treated with ampicillin and all patients treated with trimethoprim-sulfamethoxazole responsed promptly and comparably within an average of 1.6 and 1.7 days, respectively, until stool cultures were negative, and 3.1 and 2.9 days, respectively, until diarrhea stopped. Patients with ampicillin-resistant shigellae responded to treatment with trimethoprim-sulfamethoxazole. It is concluded that trimethoprim-sulfamethoxazole is the best currently available drug for treatment of shigellosis in areas where multiple antibiotic resistance of shigellae is common.

UR - http://www.scopus.com/inward/record.url?scp=0017313203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017313203&partnerID=8YFLogxK

U2 - 10.1001/jama.235.12.1239

DO - 10.1001/jama.235.12.1239

M3 - Article

C2 - 765518

AN - SCOPUS:0017313203

VL - 235

SP - 1239

EP - 1243

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 12

ER -